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Summary statement: A meta-analysis of vitrectomy for diabetic macular edema found no significant difference in 
visual outcome compared to laser or observation. Retinal thickness was better than with laser/observation at 6 
months, but this benefit had reversed by 12 months. Intraoperative retinal breaks occurred in 7.1%, and 
postoperative retinal detachment in 1.2% 
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Abstract 
Purpose. To assess the risk and benefit of pars plana vitrectomy for diabetic macular 
edema (DME). 
Methods. We conducted a systematic literature review using PubMed, EMBASE, 
Web of Science, and Cochrane Central Database of Controlled Trials until September 
2014. The population was patients with DME, intervention vitrectomy, comparator 
macular laser or observation, and efficacy outcome visual acuity and central retinal 
thickness (CRT). Safety outcomes were intra- and postoperative surgical 
complications. The efficacy meta-analysis included only randomized controlled trials. 
The safety analysis included prospective, retrospective, controlled and uncontrolled 
studies. 
Results. Five studies were eligible for the efficacy meta-analysis (n = 127 eyes) and 
40 for the safety analysis (n = 1,562 eyes).  Combining follow up intervals from 6 to 
12 months, the meta-analysis found a non-significant 2 letter visual acuity difference 
favoring vitrectomy, and a significant 102 micron greater reduction in CRT favoring 
vitrectomy, but a post-hoc subgroup analysis found that a 6 month CRT benefit 
reversed by 12 months. The most frequent complications were retinal break (7.1%), 
elevated intraocular pressure (5.2%), epiretinal membrane (3.3%), and vitreous 
hemorrhage (2.4%). Cataract developed in 68.6% of 121 phakic eyes. 
Conclusions. Vitrectomy produces structural and functional improvements in select 
eyes with DME, but the visual gains are not significantly better than with laser or 
observation. No major safety concerns were identified. 
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Introduction 
Diabetic macular edema (DME) is a leading cause of visual loss in developed 
nations,1, 2 and as the population with diabetes expands,3 the burden of DME will 
increase. For many years the standard therapy for DME has been focal macular 
photocoagulation laser. The Early Treatment of Diabetic Retinopathy Study (ETDRS) 
established that laser approximately halves the risk of moderate vision loss in patients 
with clinically significant macular edema.4 More recently, several randomized 
controlled trials (RCTs) have demonstrated the safety and efficacy of intravitreal 
steroid injections and implants.5-9 Vascular endothelial growth factor (VEGF), by 
increasing vascular permeability, plays an important role in the pathogenesis of 
DME.10, 11 Studies investigating the intravitreal use of the anti-VEGF agents 
ranibizumab,12-16 aflibercept,2, 17 and bevacizumab18 have also shown favorable 
results.19 
 
There are a number of clinical studies suggesting that an attached vitreous may 
adversely affect the clinical course of DME, or possibly contribute to its pathogenesis. 
Sivaprasad et al found that posterior vitreous detachment (PVD) was less common in 
eyes with DME, and that vitreous attachment appeared to reduce the benefit of 
intravitreal steroid therapy.20 A synthesis of the literature by Jackson et al found that 
some degree of vitreomacular traction (VMT) was present in 12% of eyes with DME, 
and up to 24% in surgical series.21 Vitreomacular traction may aggravate any 
underlying tendency for DME, and if severe, VMT can cause macular edema in its 
own right. It therefore seems reasonable to assume that relief of VMT would be 
beneficial. 
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Several authors have advocated the use of pars plana vitrectomy (PPV) to treat DME. 
Whilst PPV is well established for the treatment of persistent vitreous hemorrhage22 
and tractional retinal detachment,23, 24 its use as a treatment for DME has not been 
supported by large randomized controlled trials (RCTs). 
 
Laboratory studies provide a theoretical basis to support the use of PPV. Several 
animal studies25-27 and some human studies28 reported that PPV increases vitreous 
oxygenation in the context of ischemia, and increased oxygen tension is likely to 
reduce VEGF. It has been estimated that vitreous viscosity is 300 to 2000 times 
greater than aqueous,29 and following vitrectomy diffusion coefficients of intravitreal 
molecules, including VEGF, should increase by a similar magnitude.30 Therefore, 
following PPV, VEGF and other pro-inflammatory cytokines would be expected to 
diffuse away from the macula more easily.31 Conversely, the post-vitrectomy decrease 
in the viscosity of the vitreous cavity has the possible disadvantage of interfering with 
intraocular pharmacokinetics and reducing the half-life of intravitreal drugs.32 
 
In the absence of large RCTs of PPV for DME we aimed to undertake a systematic 
review and meta-analysis to assess if PPV is an appropriate surgical intervention. 
Specifically, we aimed to determine the benefit of PPV in terms of the mean change 
in visual acuity (VA) and reduction in optical coherence tomography (OCT) central 
retinal thickness (CRT), and the risk in terms of intra- and postoperative 
complications. An analysis of risk and benefit is particularly important in the context 
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of new intravitreal drug treatments that have proven efficacy and favorable safety 
profiles - interventions that do not expose patients to the risks of PPV.  
 
Methods 
Study design, population, intervention, comparison and outcome 
We aimed to estimate the risk and benefit of PPV for DME. To estimate the potential 
benefit of PPV we used a meta-analysis of efficacy outcomes, selecting only RCTs. 
To estimate the risks of PPV, in terms of surgical complications, we undertook a 
systematic review, to encompass a wider range of literature and increase the 
likelihood of detecting rare events. The population was patients with DME, the  
intervention was PPV, and the comparison was traditional standard care,4 namely 
focal macular photocoagulation laser or observation. The two main efficacy outcomes 
were visual acuity (VA), and optical coherence tomography (OCT) central retinal 
thickness (CRT). Safety outcomes included all reported intra- or postoperative 
surgical complications, or other adverse events attributed to PPV or local or general 
anesthesia. The study protocol was registered with the international prospective 
register of systematic reviews (registration number CRD42014013646, National 
Institute of Health Research Centre for Reviews and Dissemination, University of 
York, UK) and conducted in accordance with Preferred Reporting Items for 
Systematic reviews and Meta-Analyses (PRISMA) guidance (http://www.prisma-
statement.org/, accessed 21 January 2015). 
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Eligibility  
To be eligible for the meta-analysis RCTs had to recruit patients with DME, and 
compare PPV to traditional standard care (observation or macular photocoagulation 
laser), for the treatment of DME. Outcome data had to include change in VA and 
change in CRT at least 6 months after enrolment, and safety at any time point. The 
data had to be of sufficient quality, in terms of clear eligibility, defined efficacy and 
safety outcomes, and data completeness, and in particular studies had to report any 
complications that occurred, or state that there were none.  Only English, French and 
German language articles in peer-reviewed journals were eligible. Studies that failed 
to provide pre- and post-operative VA were excluded, as were those appearing as 
abstract only, and studies where patients received adjunctive therapy such as 
intravitreal steroids and anti-VEGF drugs, as these could confound the analysis of 
vitrectomy versus laser/observation. Editorials, expert opinions, and articles in non-
peer reviewed journals were excluded. Articles using intravitreal vital stains to assist 
with peeling of the internal limiting membrane (ILM) were not excluded.33-36 Similar 
eligibility criteria were applied to the safety analysis, except that studies did not need 
to be RCTs or have a control group, the minimum VA follow up did not apply, and 
they need not report CRT. Prospective, retrospective, controlled and uncontrolled 
studies, including case reports, were eligible for the safety analysis.  
 
Literature review 
An Ovid MEDLINE database search from 1946 to 23 September 2014 was 
undertaken using Boolean operators with the following keywords (and corresponding 
MESH headings if they were available): vitrectomy; diab*; macula*; oedema or 
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edema; maculopathy; vitreomacular traction; vitreomacular adhesion; taut posterior 
hyaloid. The search was not restricted by adding terms such as adverse events, 
complications, or safety, but rather each eligible article was reviewed for safety data. 
Searches were repeated using EMBASE™ (Ovid), and the Cochrane Central 
Database of Controlled Trials (CENTRAL, Cochrane library). An example search is 
shown in eAppendix 1 (see Supplement).  
 
The retrieved abstracts were then reviewed by two senior retinal experts (TJ, EP) who 
selected articles for full review if they appeared to meet the eligibility criteria. Further 
articles were identified in the bibliographies of retrieved articles. Where necessary, 
authors were contacted to obtain unpublished raw data from RCTs.  
 
Data extraction 
Three independent reviewers (FG, AA, EN) entered data from each article into an 
electronic data capture form. Any discrepancy was resolved by consensus or, if 
necessary, by arbitration of a senior retinal specialist (TJ). The protocol for data 
collection included the following information for each article: 1) general information 
about the study (aim, summary, key findings); 2) methodological details (study 
design, study population, entry criteria, methods, study period); 3) primary and 
secondary outcomes; 4) presenting and final VA; 5) whether or not eyes underwent 
peeling of the ILM at the time of PPV; 6) safety outcomes (adverse events and serious 
adverse events, including surgical complications and reoperations).   
 
Assessment of bias 
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The risk of bias was assessed using the Cochrane Risk of Bias Assessment tool which 
grades risk of bias as low, unclear or high risk. Seven domains of risk where assessed 
including assessments for selection bias, performance bias, detection bias, attrition 
bias and reporting bias. 
 
Data analysis 
To analyse visual outcome across studies the mean VA data were converted to 
logarithm of the minimum angle of resolution (LogMAR) units.37 Counting fingers 
vision was assigned a LogMAR acuity of 1.6, hand movements 1.9, light perception 
2.2, and no light perception 2.5.38-40 Meta-analysis was used to pool comparisons of 
the mean change in LogMAR VA and change in CRT comparing PPV and control 
(observation or laser). The fixed effect method with inverse variance weighting was 
used. Statistical analysis was performed using RevMan 5.2 available from the 
Cochrane Collaboration.41  Safety data were pooled across all studies, including non-
RCTs.  
 
Results 
Meta-analysis of efficacy: 
Six RCTs were identified that provided mean change in LogMAR VA and mean 
change in retinal thickness, comparing patients having undergone PPV with 
controls.42-47  One study was excluded, as it was not possible to obtain raw data or 
summary statistics for the outcomes in question, despite contacting the author 
(eAppendix 2, see supplement).47 Additional, anonymous participant-level data were 
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obtained from two study authors, such that their reports could be included in the meta-
analysis.45, 46  Of the five RCTs included, four used a laser control group42, 43, 45, 46 and 
one used an untreated control group44. We identified possible duplicate reporting in 
two studies43, 44, but concluded these were different populations given the different 
eligibility criteria and control groups.  Follow up duration was 6 months in 3 studies42, 
44, 46 and 12 months45, 46 in 2 (one study reported both outcomes46) (Table 1).  One 
study46 reported results at 6 and 12 months, where 5 patients were double counted for 
the LogMAR results and 6 patients for the CRT.  Sensitivity analysis was performed 
to test the effect on the results by excluding the 6 month or 12 month outcome.  This 
resulted in similar magnitude and precision of results. We preferred to report the 
combined results (at 6 and 12 months) due to the greater sample size. This 
summarizing error was considered acceptable as sensitivity analysis testing showed it 
did not affect the conclusion. 
 
All RCTs appeared to be at low risk of reporting bias (Figures 1A and 1B).  It is not 
possible to effectively mask patients to the intervention, vitrectomy, observation or 
control, and as such all studies are at risk of introducing performance bias. Detection 
bias may have been minimized by using masked assessors for VA outcome collection, 
although only 2 out of 5 studies explicitly stated doing this.44, 48 It was felt that the 
collection of automated OCT central retinal thickness data was unlikely to introduce 
bias whether masked assessors were used or not. Randomization methodology and 
allocation concealment were not always explicitly reported across the trials (see 
eAppendix 3 in the Supplement).
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Table 1. Randomized controlled study characteristics included in the meta-analysis, showing visual acuity and central retinal thickness before and after pars 
plana vitrectomy 
  Thomas 2005 Yanyali 2005 Yanyali 2006 Patel 2006 Kumar 2007 
Patient population 33 eyes of 33 patients 
with DME, VA of 0.3 
logMAR or worse, 
after one or more 
macular laser 
treatments 
24 eyes of 12 patients 
with DME in both eyes. 
One eye used as control. 
20 eyes of 10 patients 
with DME in both eyes. 
One eye used as contol. 
Patients were 
unresponsive to grid 
laser photocoagulation 
12 eyes from 12 patients with 
persistent clinically significant 
DME despite previous macular 
laser. 
24 eyes of 24 
patients with 
diffuse DME.  
Males (%) 70 41.7 40 58 91.7 
Mean follow-up 
period (months) 
12 6 12 6 and 12 6 
Intervention PPV + ILM peeling PPV + ILM peeling PPV + ILM peeling Standard three-port PPV with 
elevation and the removal of 
the posterior vitreous 
cortex (no ILM peeling) 
PPV + ILM peeling 
Treated eyes 
(number) 
15 12 10 7 12 
Mean age (years) 64.3 64.4 61.5 63 (all) 57.25 
LogMAR VA ± 1SD 
before (Snellen) 
0.67 ± 0.30 
(20/94) 
0.75 ± 0.40 
(20/112) 
0.72 ± 0.43 
(20/105) 
0.55 ± 0.18 
(20/71) 
1.11 ± 0.09 
(20/258) 
LogMAR  VA ± 1SD 
after (Snellen) 
0.71 ± 0.33 
(20/103) 
0.54 ± 0.40 
(20/69) 
0.55 ± 0.45 
(20/71) 
0.5 ± 0.22 (20/63) (6 eyes/6 
months)  
0.57  ± 0.18 (20/74) (6 eyes/12 
months) 
0.92 ± 0.10 
(20/166) 
CRT ± 1SD before 
(μl) 
426.2 ± 111.2 439.3 ± 102.0 391.3 ± 91.6 375.3 ±144.8 567.5 ± 147.9 
CRT ± 1SD after 
(μl) 
347.1 ± 202.9 219.8 ± 60.6 225.5 ± 49.5 318.2 ± 114.8 (6 eyes/6 
months) 
266.6 ± 69.4 
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334.17 ± 112.0 (6 eyes/12 
months) 
Control  Macular laser Modified grid laser 
photocoagulation 
Untreated controls Laser Modified grid laser 
photocoagulation 
Control eyes 
(number) 
18 12 10 8 12 
Mean age (years) 64 64 62 63 (all) 57 
LogMAR VA ± 1SD 
before (Snellen) 
0.62 ± 0.23 
(20/83) 
0.59 ± 0.26 
(20/78) 
0.44 ± 0.44 
(20/55) 
0.50 ± 0.25 
(20/63) 
1.07 ± 0.06 
(20/235) 
LogMAR  VA ± 1SD 
after (Snellen) 
0.57 ± 0.32 
(20/74) 
0.50 ± 0.26 
(20/63) 
0.60 ±0.56 
(20/80) 
0.42 ± 0.22 (20/53) (8 eyes/6 
months) 
0.31 ±0.13 (20/40) (6 eyes/12 
months) 
0.97 ± 0.09 
(20/186) 
CRT ± 1SD before 
(μl) 
440.3 ± 172.8 407.1 ± 96.0 356.2 ± 140.1 404.5 ± 145.8 463.6 ± 92.4 
CRT ± 1SD after 
(μl) 
330.0 ± 117.7 378.5 ± 135.6 318.4 ± 111.1 320.63 ± 114.0 (8 eyes/6 
months) 
308.2 ± 123.1 (6 eyes/12 
months) 
357.0 ± 77.21 
 
Footnote: VA: visual acuity; CRT: central retinal thickness; DME: diabetic macular edema; ILM peel: internal limiting membrane peeling; PPV: pars plana 
vitrectomy; SD: standard deviation; VA: visual acuity.  
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Figure 1. Risk of bias summary and graph. 
 
 
Figure 1 illustrates the risk of bias summary (A) and the risk of bias graph (B). The 
review is based on the authors' judgements about each risk of bias item for each 
included study. The risk of bias in each paper was evaluated for across seven 
domains. Each domain was rated as either Low Risk, Unclear Risk or High Risk of 
introducing bias.  
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Abbreviations: + low risk; ? unclear risk; - high risk. 
 
Figure 2 shows a forest plot of the vision outcome (mean change in VA in LogMAR 
units) from the meta-analysis of the five RCTs, comparing PPV with control. Overall 
there was a 2 letter (0.04 logMAR units) difference favoring PPV over control but this 
was not significant (95% confidence interval [CI] -0.02 to 0.1 logMAR units, 
p=0.18). 
 
As part of the iterative process and in accordance with PRISMA guidance, the 
original analysis protocol was adapted to accommodate the variability in the follow 
up interval reported (6 or 12 months) and control group (observation or laser). 
Specifically, we undertook a post-hoc analysis of the main efficacy outcome measures 
(change in mean VA and CRT) in three subgroups: 1) studies reporting outcomes at 6 
months with laser control; 2) studies reporting at 12 months with laser control; and 3) 
studies reporting at 12 months with untreated controls. In the laser controlled studies, 
using mean VA at 6 months there was an almost significant (p=0.05) benefit from 
vitrectomy compared to laser, however this reversed at 12 months, with an almost 
significant result favoring laser (p=0.07). The subgroup analyses are shown in Figure 
2. Within each subgroup the results were similar, however on combining all 3 
subgroups there was moderate heterogeneity (I2 of 60%). 
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Figure 2. Meta-analysis of vision outcome comparing pars plana vitrectomy to standard care 
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Figure 3. Meta-analysis of change in optimal coherence tomography macular thickness comparing pars plana vitrectomy to standard 
care 
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Figure 2 shows a meta-analysis of vision outcome (change in mean logarithm of the minimum angle of visual acuity), comparing pars plana 
vitrectomy to standard care (observation or macular laser). The overall analysis of the five RCTs showed a better visual outcome in the 
vitrectomy group, but this was not quite significant and there was heterogeneity amongst the trials.  
Abbreviations: CI = confidence interval; IV = Inverse variance method used; Fixed= Fixed effect model used; SD = standard deviation. 
 
Figure 3 presents a meta-analysis of change in optical coherence tomography macular thickness, comparing pars plana vitrectomy or standard 
care (observation or macular laser). The overall analysis showed that vitrectomy resulted in a significantly greater reduction in macular thickness 
than standard care. 
Abbreviations: CI = confidence interval; IV = Inverse variance method used; Fixed= Fixed effect model used; SD = standard deviation. 
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Figure 3 presents a forest plot of the meta-analysis of the same five RCTs, with 
respect to change in CRT. Overall there was a significant, 102 m (95% CI 61 to 
144m, p<0.00001) greater reduction in macular thickness in the pooled vitrectomy 
group compared with the control group (I2 of 78%). However, as can be seen in 
Figure 3, the subgroup analysis suggested that the advantage of PPV over laser at 6 
months was not evident at 12 months.   
 
Safety:  
A total of 425 abstracts were retrieved. Of these 106 potentially eligible articles were 
reviewed in full, of which 40 were eligible for the safety analysis. Although the 
literature search extended back to 1946, the first eligible report was published in 
1992,3 and 38 of 40 were published after 2000 (eAppendix 4, see supplement).  
 
In 40 studies, intra- and postoperative complications were reported (Table 2).3, 42-44, 46, 
48-82 The most frequent intraoperative surgical complications were peripheral retinal 
break (7.08% of 1,469 eyes), iatrogenic tears (0.68% of 1,469 eyes), and focal, 
petechial spontaneously resolving retinal hemorrhage (0.34% of 1,469 eyes). The 
most frequent postoperative complications were raised intraocular pressure (5.19% of 
1,562 eyes), epiretinal membrane (3.27% of 1,562 eyes), vitreous hemorrhage (2.43% 
of 1,562 eyes), neovascular glaucoma (1.60% of 1,562 eyes), glaucoma (1.41% of 
1,562 eyes), macular hard exudates (1.34% of 1562 eyes) and retinal detachment 
(1.22% of 1,562 eyes). 
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Table 2. Intra- and postoperative complications3,42-44,46,48-82 
Intra-operative complications 
Number of 
eyes 
Number of 
eyes 
affected 
Eyes 
affected (%) 
Peripheral retinal break 1469 104 7.08% 
Iatrogenic tears 1469 10 0.68% 
Focal, petechial, spontaneously resolving retinal 
hemorrhage 1469 5 0.34% 
Retinal detachment 1469 2 0.14% 
Entry site break 1469 1 0.07% 
    post-operative complications 
   Cataract* 1562 40 2.56% 
Cataract surgery 1562 19 47.50% 
Intraocular pressure 1562 81 5.19% 
Epiretinal membrane 1562 51 3.27% 
Vitreous hemorrhage 1562 38 2.43% 
Neovascular glaucoma 1562 25 1.60% 
Glaucoma 1562 22 1.41% 
Hard exudate deposits in the center of the 
macula 1562 21 1.34% 
Retinal detachment 1562 19 1.22% 
Mild progression of nuclear sclerosis 1562 12 0.77% 
Rhematogenous retinal detachment 1562 10 0.64% 
Cystoid macular edema 1562 6 0.38% 
Macular retinal pigment epithelium 
abnormalities 1562 5 0.32% 
Ocular hypertension 1562 4 0.26% 
Neovascularisation of the angle 1562 3 0.19% 
Secondary Glaucoma 1562 3 0.19% 
APE atrophy of the macula 1562 3 0.19% 
Unusual refex of the retinal surface 1562 3 0.19% 
Ischemic optic neuropathy 1562 3 0.19% 
Endophthalmitis 1562 3 0.19% 
Lipid deposit in the centre of the macula 1562 3 0.19% 
Central retinal vein occlusion 1562 2 0.13% 
Full-thickness macular hole 1562 1 0.06% 
Dissociated optic nerve fiber layer appearance 1562 1 0.06% 
Posterior vitreous detachment 1562 1 0.06% 
Lamellar macular hole 1562 1 0.06% 
Choroidal neovascularization 1562 1 0.06% 
Deterioration of existing cataract 1562 1 0.06% 
Partial thickness macular hole 1562 1 0.06% 
Retinal hemorrhage 1562 1 0.06% 
*Cataract developed in 68.6% of 121 phakic eyes  
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The rate of post-vitrectomy cataract was not reliably reported and many reports did 
not detail the proportion of phakic eyes. Cataract was reported to develop in only 40 
of 1,562 eyes (2.56%), of which 47.5% (19 of 40 eyes) underwent subsequent cataract 
surgery. Four studies provided the post-vitrectomy cataract rate in 121 phakic eyes, 
and 83 (68.6%) of these eyes developed cataract over a mean of 31.0 months.57, 65, 67, 
70 
 
A post hoc safety analysis was undertaken using the data from the RCTs included in 
the efficacy meta-analysis, to assess if the complication rates differed from those 
reported in the main safety analysis (which included uncontrolled and retrospective 
studies). The complication rates appeared similar in the 46 participants with detailed 
safety reporting, in that the most common complication was progression of nuclear 
sclerosis (23.9%) followed by raised intraocular pressure (6.5%). The only other 
complication reported was rhegmantogenous retinal detachment in one patient 
(2.1%).42-44, 46  
  
Discussion 
Our meta-analysis of RCTs suggests that the visual benefits following vitrectomy for 
DME were not significantly better than those achieved using conventional 
management with laser and observation. The RCTs indicated that PPV was associated 
with a significantly greater reduction in macular thickness than laser and observation, 
but there was heterogeneity in this overall result, and our subgroup analysis may be 
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more informative. This showed a trend for better OCT results than with laser at 6 
months, but this trend had reversed by 12 months.  
 
The VA gain in the RCTs was equivalent to 2 ETDRS letters (0.04 LogMAR). The 
Ranibizumab for Edema of the mAcula in Diabetes (READ-2) study randomized 
patients with DME to receive ranibizumab, macular laser, or both.14 In the group 
receiving only ranibizumab, vision improved by an average of 7.4 letters at 6 months. 
Another RCT compared ranibizumab alone, and in combination with macular laser, 
and reported a mean gain of 6.1 letters at 12 months in the group that only received 
ranibizumab.15 Yet another study showed a 5.8 letter gain following ranibizumab and 
deferred laser.16 As such the PPV RCT results do not compare favorably with those of 
anti-VEGF therapy in terms of the mean VA change (or in relation to the comparison 
with a laser control group). However, ddirect comparison between the anti-VEGF 
studies and our meta-analysis is difficult for several reasons. Key amongst these is 
that vitrectomy is often reserved for patients who have failed other treatments, 
whereas anti-VEGF agents are often used as a first-line treatment. Ideally, there 
would be RCTs directly comparing PPV and anti-VEGF treatments.  
 
No major safety concerns were identified. Retinal breaks were the most common 
complication. A database study of 8,257 PPVs also found that retinal breaks were the 
most common intraoperative complication.83 In the subset of eyes undergoing 
epiretinal membrane surgery, a PPV of similar complexity, iatrogenic retinal breaks 
occurred in 3.0% of cases, whereas the present series incorporated studies that used 
somewhat varying terminology, with those describing ‘peripheral retinal breaks’ 
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averaging a 7.1% rate, and those reporting ‘iatrogenic tears’ averaging 0.7%.  Retinal 
detachment occurred in 1.5% of the epiretinal membrane cases, compared with 1.2% 
in the present analysis. The incidence of post-vitrectomy hemorrhage and neovascular 
glaucoma were higher in the present series, consistent with an underlying diagnosis of 
diabetes. Although the safety of PPV for DME appears comparable to other studies of 
PPV, the complication rates are higher than those seen following intravitreal anti-
VEGF injections for DME.13, 15, 16  
   
The main strength of the present meta-analysis is that it provides a pooled estimate of 
treatment effect across several RCTs, and the safety analysis considers an even larger 
pool of patients that may be better able to detect rare events. There is a risk that 
publication or reporting bias may favor the selection of reports describing positive 
surgical outcomes.84, 85 Also, post-vitrectomy lens changes may be a confounding 
variable. It was not possible to determine the lens status in many studies, or to reliably 
determine the proportion of eyes that underwent cataract surgery. It is well known 
that PPV causes cataract and this is likely to reduce the mean visual gain, and this is 
possibly suggested by the worse VA outcome at 12 months compared to 6 months, as 
shown in Figure 2 (this would not however explain a worsening of the OCT outcome 
over this timeframe). Conversely, removal of preexisting lens opacity during initial 
combined phakovitrectomy, or subsequently as a result of post-vitrectomy cataract, 
will tend to improve the mean VA of the PPV group.  Although laser or observation 
remain the standard of care for many patient, anti-VEGF therapy is now emerging as 
a standard of care for many other patients. Our results suggest that PPV is not 
superior to laser or observation, and the pivotal anti-VEGF trials in turn show that 
anti-VEGF treatment is superior to laser; this might appear to indicate that anti-VEGF 
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therapy is superior to PPV, that analysis requires direct comparison of PPV versus 
anti-VEGF therapy, and is not proven by our analysis. 
 
Another intrinsic difficulty of studies involving PPV is that masking is not possible, 
as sham surgery would not be practical. However most of the RCTs provided 
relatively robust VA assessment and lack of masking is unlikely to materially 
influence CRT measurement, which relies on automated computer software analysis.  
 
Interventional case series recruit patients in whom surgery is considered clinically 
reasonable, and those with milder disease may have been excluded.86 Therefore the 
results may not be representative of all patients with DME, or comparable with 
studies investigating intravitreal injections. Also, even if the overall functional benefit 
was no better than macular laser, it is possible that a subgroup of patients with DME 
and significant vitreomacular traction may benefit from PPV. Vitreomacular traction 
or taut posterior hyaloid is reported to be present in 17% of DME cases undergoing 
PPV.21  
 
In summary, this study found that PPV produced both structural and functional 
benefit in eyes with DME, but the functional benefit was not significantly better than 
that obtained using macular laser, and the structural benefits appeared to decline, or 
possibly reverse, with time. Like previous reviews,21 we identified a lack of high 
quality evidence, and the need for large RCTs comparing PPV to the latest gold 
standard, in particular intravitreal anti-VEGF drugs. Given the favorable results with 
these newer treatments, the need to justify PPV becomes even greater. 
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Appendix 1 Search Strategy 
Illustrative literature search using OvidSP (EMBASE) to retrieve studies of pars plana 
vitrectomy for the treatment of diabetic macular edema. 
 Searches Results 
1 edema.mp. or edema/ 225,844 
 
2 oedema.mp. [mp=title, abstract, subject headings, heading word, 
drug trade name, original title, device manufacturer, drug 
manufacturer, device trade name, keyword] 
27,735 
 
3 1 or 2 23,4960 
 
4 retina macula lutea/ or macula*.mp.  57,065 
 
5 3 and 4 13,297 
 
6 macular edema.mp. or retina macula edema/ 10,492 
 
7 macular oedema.mp. 1,441 
 
8 5 or 6 or 7 13,297 
 
9 diabetes mellitus/or diabet*.mp. 722,041 
 
10 8 and 9  5,351 
 
11 diabetic macular edema/ 2,040 
 
12 10 or 11 5,351 
 
13 vitrectomy.mp. or vitrectomy/ 18,637 
 
14 12 and 13 950 
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Appendix 2. PRISMA 2009 Flow Diagram (Efficacy Analysis) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Records identified through 
database searching 
(n = 425) 
Sc
re
e
n
in
g 
In
cl
u
d
e
d
 
El
ig
ib
il
it
y 
Id
e
n
ti
fi
ca
ti
o
n
 Additional records identified 
through other sources 
(n =0) 
Records after duplicates removed 
(n = 425) 
Records screened 
(n = 425) 
Records excluded 
(n =319) 
Full-text articles assessed 
for eligibility 
(n = 106) 
Full-text articles excluded, 
with reasons 
(n = 101 non RCT studies) 
Studies included in 
qualitative synthesis 
(n =  5) 
Studies included in 
quantitative synthesis 
(meta-analysis) 
(n = 5) 
 39 
Appendix 3. Risk of Bias Summary of Included Studies 
Study:  Kumar 2007 
Methods 
Randomized controlled trial 
Participants 24 Eyes. Visual acuity ≤ 6/60, diffuse macular edema, HbA1C > 7.5%, study 
based in India. 
Excluded patients with fundus fluorescein angiogram (FFA) evidence of 
macular ischemia, vitreomacular traction, cataract surgery within 1 year, 
previous vitrectomy, previous panretinal photocoagulation (PRP) in 
12months, previous grid laser in 6 months, uncontrolled diabetes, 
hypertension or chronic renal failure 
Interventions Pars plana vitrectomy (PPV) with dye-assisted internal limiting membrane 
(ILM) peel or grid LASER. No triamcinolone used 
Outcomes Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity (VA), 
macular thickness, macular volume at 6 months 
 
Bias 
Authors 
judgement 
Support for judgement 
Random sequence generation 
(selection bias) 
Unclear 
Randomisation method not mentioned 
Allocation concealment 
(selection bias) 
Unclear Randomisation concealed by sealed 
envelop 
Blinding of participants and 
personnel (performance bias) 
High risk 
Patients not masked (vitrectomy or laser) 
Blinding of outcome 
assessment (detection bias) 
Unclear 
No mention if assessors were masked 
Incomplete outcome data 
(attrition bias) 
Low risk 
25 patients assessed, 24 eyes analysed 
Selective reporting (reporting 
bias) 
Low risk 
All outcomes reported 
Other bias Low risk  
 
  
 40 
 
Study: Patel 2006 
Methods 
Randomized controlled trial 
Participants 20 patients recruited, 7 vitrectomy patients, 8 laser patients 
Clinically significant macular edema (CSME) depsite previous macular laser 
(less than 2years), Snellen acuity 6/15- 6/60 (65- 35 letters) 
Excluded macular ischemia 
Interventions 
Vitrectomy (ILM not peeled) (7 patients) or macular laser (8 patients) 
Outcomes ETDRS VA, optical coherence tomography (OCT), and FFA at baseline and 12 
months 
 
Bias 
Authors 
judgement 
Support for judgement 
Random sequence generation 
(selection bias) 
Low risk Randomisation performed by separate 
department in same hospital. 
Comment: Probably done 
Allocation concealment 
(selection bias) 
High risk 
Concealment method not described 
Blinding of participants and 
personnel (performance bias) 
High risk 
Patients can not be masked to 
intervention 
Blinding of outcome 
assessment (detection bias) 
Low risk 
Masked observers 
Incomplete outcome data 
(attrition bias) 
Low risk 
20 patients recruited, 15 analysed- similar 
attrition in each group 
Selective reporting (reporting 
bias) 
Low risk 
All outcomes reported 
Other bias Low risk  
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Study: Thomas 2005 
Methods 
Randomized controlled trial 
Participants Diabetic macular edema with no macular traction 
Previous macular laser 
VA 6/12 or worse 
Excluded ischemic maculopathy 
Interventions 19 patients randomised to vitrectomy with ILM peel compared to 21 control 
patients undergoing further macular laser 
Outcomes Best corrected logarithm of the minimum angle of resolution (LogMAR) VA 
and mean OCT central macular thickness 
 
Bias 
Authors 
judgement 
Support for judgement 
Random sequence generation 
(selection bias) 
Low risk 
Randomization prepared by independent 
medical statistician 
Allocation concealment 
(selection bias) 
Low risk 
Sealed, numbered opaque envelopes used: 
probably adequate 
Blinding of participants and 
personnel (performance bias) 
High risk 
Unable to mask patients 
Blinding of outcome 
assessment (detection bias) 
Unclear 
risk No mention if assessors were masked 
Incomplete outcome data 
(attrition bias) 
Low risk Similar loss to follow up in both groups 
(vitrectomy group loss 4/19, laser control 
group loss 3/18) 
Selective reporting (reporting 
bias) 
Low risk All outcomes reported 
Intention to treat analysis used 
Other bias Low risk  
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Study: Yanyali 2005 
Methods 
Randomised controlled trial 
Participants 12 patients, 24 eyes 
Bilateral diabetic macular edema 
Type 2 diabetes 
No vitreomacular traction 
No previous laser 
Interventions 12 eyes vitrectomy with ILM peeling 
Fellow 12 eyes undergo macular laser 
Outcomes 
Best corrected LogMAR VA and mean OCT central macular thickness 
 
Bias 
Authors 
judgement 
Support for judgement 
Random sequence generation 
(selection bias) 
High risk 
Method of randomisation not explained 
Allocation concealment 
(selection bias) 
High risk 
Method of concealment not explained 
Blinding of participants and 
personnel (performance bias) 
High risk 
Participant not masked 
Blinding of outcome 
assessment (detection bias) 
Unclear 
risk No mention if assessors were masked 
Incomplete outcome data 
(attrition bias) 
Low risk 
Full follow up 
Selective reporting (reporting 
bias) 
Low risk 
All outcomes reported 
Other bias Low risk  
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Study: Yanyali 2006 
Methods 
Randomized controlled trial 
Participants 10 patients, 20 eyes 
Bilateral diabetic macula edema 
Type 2 diabetes 
All had previous grid laser and now considered 'unresponsive to further laser' 
No vitreomacular traction 
Interventions 10 eyes underwent vitrectomy with ILM peeling 
10 fellow eyes followed observation alone 
Outcomes 
OCT retinal thickness and visual acuity 
 
Bias 
Authors 
judgement 
Support for judgement 
Random sequence generation 
(selection bias) 
High risk 
Method of randomization not explained 
Allocation concealment 
(selection bias) 
High risk 
Method of concealment not explained 
Blinding of participants and 
personnel (performance bias) 
High risk 
Unable to mask patients 
Blinding of outcome 
assessment (detection bias) 
Low risk 
Assessor was masked to treatment groups 
Incomplete outcome data 
(attrition bias) 
Low risk 
No patients lost to follow up 
Selective reporting (reporting 
bias) 
Low risk 
All outcomes reported 
Other bias Low risk  
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Appendix 4. PRISMA 2009 Flow Diagram (Safety Analysis). 
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